Nuclear medicine techniques in the evaluation of pharmaceutical formulations

Pharmacy World and Science

Volumn 18, Issue 3, 1996, Pages 97-104

  Perkins, A C ^a   Frier, M ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

drug formulations; drug targeting; scintigraphy

Indexed keywords

ERBIUM 170; INDIUM 111; IODINE 123; RADIOISOTOPE; SAMARIUM 153; TECHNETIUM 99M; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG FORMULATION; NUCLEAR MEDICINE; REVIEW; TECHNOLOGY;

EID: 0029894696     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00417757     Document Type: Review

References (48)

1. Wilson CG, Hardy JG, Frier M and Davis SS. Eds Radionuclide imaging in drug research. Croom Helm, London 1982.
2. Wilson CG and Perkins AC. Gamma Scintigraphy and the study of drug deposition. In: Advances in Pharmaceutical Sciences. Eds. Ganderton D and Jones T. Academic Press, London, 1992.
3. Davis SS, Hardy JG, Newman SP, Wilding IR. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms. Eur J Nucl Med 1992; 19:971-986.
4. Burns HD, Gibson RE, Dannals and Siegl PKS. Eds. Nuclear Imaging in drug discovery, development and approval. 1993, Birkhauser, Boston.
5. Meseguer G, Buri P, Gurny R. Application of medical imaging to pharmaceutical research: The example of gamma scintigraphy: I. Technological aspects. European Journal of Pharmaceutics and Biopharmaceutics, 1994;40:111-121.
6. Meseguer G, Gurny R, Buri P. In vivo evaluation of dosage forms: Application of gamma scintigraphy to non-enteral routes of administration. Journal of Drug Targeting. 1994;2:269-288.
7. Tolin R D, Malmud L S, Reilley J, Fisher R S. Oesophageal scintigraphy to quantitate oesophageal transit (Quantitation of oesophageal transit). Gastroenterology 1979;76:1402-1409.
8. Davis SS, Daly PB, Frier M, Hardy JG Kennerley JW, Wilson CG. The design and evaluation of sustained release formulations for oral and buccal administration. Adv Pharmacother 1981;1:17-25.
9. Daly PB, Davis SS, Frier M, Hardy JG, Kennerly JW, Wilson CG. Scintigraphic assessment of the in-vivo dissolution rate of a sustained release tablet. Int J Pharm 1982;10:17-24.
10. Davis SS, Hardy JG, Taylor MJ, Stockwell A, Whalley DR, Wilson CG. The in-vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy. J Pharm Pharmacol 1984;36:740-742.
11. Davis SS, Hardy JG, Taylor MJ, Stockwell A, Whalley DR, Wilson CG. The effect of food on the gastrointestinal transit of pellets and an osmotic device. Int J Pharm 1984;21:331-340.
12. May HA, Wilson CG, Hardy JG. Monitoring radiolabelled antacid preparations in the stomach. Int J Pharmaceutics 1984;19:169-176.
13. 3 Hardy JG, Wilson CG, Wood E. Drug delivery to the proximal colon. J Pharm Pharmacol 1985; 37:874-877.
14. Parr AF, Beihn RM, Franz RM, Szpunar GJ, Jay M. Correlation of ibuprofen bioavailability with gastrointestinal transit by scintigraphic monitoring of 171Er labelled sustained-release tablets. Pharm Res 1987;4:486-489.
15. Ollerenshaw KJ, Norman S, Wilson CG and Hardy JG. Exercise and small intestinal transit. Nucl Med Commun. 1987; 8:105-110.
16. Mundy MJ, Wilson CG, Hardy JG. The effect of eating on transit through the small intestine. Nucl Med Commun. 1989;10:45-50.
17. Wilson CG, Washington N, Greaves JL, Blackshaw PB, Perkins AC, Barkworth MF, Rehm KD. Effect of pretreatment with ranitidine on the transit of a sustained release theophylline preparation. Arzneimittel-Forschung Drug Research 1991;41:1154-1159.
18. Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 1991;8:360-364.
19. Davis SS, Robertson C, Wilding IR. Gastrointestinal transit of a multiparticulate tablet formulation in patients with active ulcerative colitis. Int J Pharm 1991;199-204.
20. Roca M, Carrio I, Monés J, Mora J, Estorch M, Berná L. Labelling procedure of antacid preparations using 99mTc-prophosphate. Int J Pharmacol. 1991;69:189-192.
21. Monés J, Carrio I, Rocca M et al. Gastric emptying of two radiolabelled antacids. Gut 1991;32:147-150.
22. Coupe AJ, Davis SS, Evans DF, Wilding IR. Correlation of the gastric emptying of non-disintegrating tablets with gastrointestinal motility. Pharm Res 1991;8:1281-1285.
23. Course NJ, Newton JM, Short MD. Stomach outline visualization in gastrointestinal transit studies using scintigraphy. Journal of Pharmacy and Pharmacology, 1992;44:127-129.
24. Coupe AJ, Davis SS, Evans DF, Wilding IR. The effect of sleep on the gastrointestinal transit of pharmaceutical dosage forms. International Journal of Pharmaceutics, 1992;78:69-76.
25. Washington N, Moss HA, Washington C, Greaves JL, Steele RJC, Wilson CG. Non-invasive detection of gastro-oesophageal reflux using an ambulatory system. Gut, 1993;34:1482-1486.
26. Washington N, Wilson CG, Williams DL, Robertson C. An investigation into the effect of cimetidine pre-treatment on raft formation of an anti-reflux agent. Alimentary Pharmacology and Therapeutics 1993;7:553-559.
27. Clarke GM, Newton JM, Short MD. Gastrointestinal transit of pellets of differing size and density. International Journal of Pharmaceutics 1993;100:81-92.
28. Hardy JG, Harvey WJ, Sparrow RA, Marshall GB, Steed KP, Macarios M, Wilding IR. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa(R)) in the gastrointestinal tract using gamma scintigraphy. Journal of Clinical Pharmacology. 1993;33:712-718.
29. Davis SS, Wilding EA, Wilding IR. Gastrointestinal transit of a matrix tablet formulation: Comparison of canine and human data. International Journal of Pharmaceutics 1993;94:235-238.
30. Ashford M, Fell JT, Attwood D, Sharma H, Woodhead PJ. An in vivo investigation into the suitability of pH dependent polymers for colonic targeting. International Journal of Pharmaceutics 1993;95:193-199.
31. Price JMC, Davis SS, Wilding IR. Characterization of colonic transit of nondisintegrating tablets in healthy subjects. Digestive Diseases and Sciences 1993;38:1015-1021.
32. Coupe AJ, Davis SS, Evans DF, Wilding IR. Do pellet formulations empty from the stomach with food? International Journal of Pharmaceutics 1993;92:167-175.
33. Abrahamsson B, Alpstein M, Hugosson M, Jonsson UE, Sundgren M, Svenheden A, Tolli J. Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets. Pharmaceutical Research 1993;10:709-714.
34. Ebel JP, Jay M, Beihn RM. An in vitro/in vivo correlation for the disintegration and onset of drug release from enteric-coated pellets. Pharmaceutical Research 1993;10:233-238.
35. Adkin DA, Davis SS, Sparrow RA, Wilding IR. Colonic transit of different sized tablets in healthy subjects. Journal of Controlled Release 1993;23:147-156
36. Davies NM, Farr SJ, Kellaway IW, Taylor G, Thomas M. A comparison of the gastric retention of alginate containing tablet formulations with and without the inclusion of excipient calcium ions. International Journal of Pharmaceutics, 1994;105:97-101.
37. Wilding IR, Davis SS, Steed KP, Sparrow RA, Westrup J, Hempenstall JM. Gastrointestinal transit of a drug-resinate administered as an oral suspension. International Journal of Pharmaceutics 1994;101:263-268.
38. Parikh R, Sweetland J, Forster ER, Bedding AW, Farr SJ, Smith JTL. Ranitidine bismuth citrate and ranitidine do not affect gastric empyting of a radio-labelled liquid meal. British Journal of Clinical Pharmacology 1994;38:577-580.
39. Sangekar SA, Sandefer EP, Page RC, Vadino WA, Saffran M, Chaudry I, Digenis GA. Comparative scintigraphic evaluation of aromatic-azo polymers and Eudragit((R)) S-100 for colonic release in beagles. Proceedings of the Controlled Release Society 1994;21:330-331.
40. Wilding IR, Davis SS, Pozzi F, Furlani P, Gazzaniga A. Enteric coated timed release systems for colonic targeting. International Journal of Pharmaceutics 1994;111:99-102.
41. Perkins AC, Wilson CG, Blackshaw PE, Vincent RM, Dansereau RJ, Juhlin KD, Bekker PJ, Spiller RC. Impared oesophageal transit of capsule versus tablet formulations in the elderly. Gut 1994;35:1363-1367.
42. Olsson B, Wagner ZG, Mansson P, Ragnarsson G. A gamma scintigraphic study of the absorption of morphine from controlled-release tablets. International Journal of Pharmaceutics 1995;119:223-
43. Kenyon CJ, Hooper G, Tierney D, Butler J, Devane J, Wilding IR. The effect of food on the gastrointestinal transit and systemic absorption of naproxen from a novel sustained release formulation. Journal of Controlled Release 1995;34:31-36.
44. Adkin DA, Davis SS, Sparrow RA, Huckle PD, Phillips AJ, Wilding IR. The effects of pharmaceutical excipients on small intestinal transit. British Journal of Clinical Pharmacology 1995;39:381-387.
45. Podczeck F, Newton JM, Yuen KH. The description of the gastrointestinal transit of pellets assessed by gamma scintigraphy using statistical moments. Pharmaceutical Research 1995;12;376-379.
46. Adkin DA, Davis SS, Sparrow RA, Huckle PD, Phillips AJ, Wilding IR The effect of different concentrations of mannitol in solution on small intestinal transit: Implications for drug absorption. Pharmaceutical Research 1995;12:393-396.
47. Monés J, Carrio I, Sainz S, Berńa L, Clavé P, Liszkay M, Rocca M, Vilardell F. Gastric emptying of two radiolabelled antacids with simultaneous monitoring of gastric pH. Eur J Nucl Med 1995;22:1123-1128.
48. Wilding IR, Davis SS, Sparrow RA, Ziemniak JA, Heald DL. Pharmacoscintigraphic evaluation of a modified release (Geomatrix(R)) diltiazem formulation. Journal of Controlled Release 1995;33:89-97.